A detailed history of Twin Tree Management, LP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Twin Tree Management, LP holds 142,300 shares of ALNY stock, worth $33.5 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
142,300
Previous 11,400 1148.25%
Holding current value
$33.5 Million
Previous $2.77 Million 1313.1%
% of portfolio
0.08%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$143.31 - $247.0 $4.05 Million - $6.98 Million
28,239 Added 182.07%
43,749 $10.6 Million
Q1 2024

May 09, 2024

BUY
$146.51 - $198.2 $2.27 Million - $3.07 Million
15,510 New
15,510 $2.32 Million
Q3 2023

Nov 14, 2023

BUY
$170.77 - $211.65 $1.07 Million - $1.33 Million
6,289 New
6,289 $1.11 Million
Q3 2022

Nov 10, 2022

BUY
$138.54 - $232.0 $8.79 Million - $14.7 Million
63,421 Added 671.83%
72,861 $14.6 Million
Q2 2022

Aug 11, 2022

SELL
$120.42 - $169.29 $2.69 Million - $3.78 Million
-22,344 Reduced 70.3%
9,440 $1.38 Million
Q1 2022

May 11, 2022

BUY
$127.18 - $173.91 $1.94 Million - $2.66 Million
15,284 Added 92.63%
31,784 $5.19 Million
Q2 2021

Aug 12, 2021

BUY
$128.63 - $176.89 $2.12 Million - $2.92 Million
16,500 New
16,500 $2.8 Million
Q4 2020

Feb 12, 2021

SELL
$122.97 - $147.0 $16,477 - $19,698
-134 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$121.19 - $165.49 $14,179 - $19,362
117 Added 688.24%
134 $20,000
Q2 2020

Aug 12, 2020

SELL
$104.21 - $156.44 $615,047 - $923,308
-5,902 Reduced 99.71%
17 $3,000
Q4 2018

Feb 13, 2019

SELL
$62.67 - $88.33 $1.18 Million - $1.66 Million
-18,788 Reduced 76.04%
5,919 $432,000
Q3 2018

Nov 09, 2018

BUY
$87.52 - $122.67 $1.42 Million - $1.98 Million
16,180 Added 189.75%
24,707 $2.16 Million
Q2 2018

Aug 08, 2018

BUY
$88.31 - $107.8 $753,019 - $919,210
8,527 New
8,527 $840,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.